Among the tested genes, MAP1LC3A showed reduction in mRNA expression in the sPD/DLB (p = 0.027; Wald Chi-Square: 4.899; B = 0.366; 95% CI [0.042: 0.691]) and GBA-PD/DLB (p = 0.012; Wald Chi-Square: 6.384; B = 0.357; 95% CI [0.080: 0.635]) group compared to controls. This evidence concerns the gene MAP1LC3A and Parkinson disease.